本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司收到控股子公司黑龙江哈三联生物技术创新 中心有限公司的通知，其对法定代表人进行了变更，并已完成工商变更登记手续， 取得了哈尔滨新区管理委员会行政审批局换发的《营业执照》。具体变更情况如 下： 变更前： 证券代码：002900 证券简称：哈三联 公告编号：2023-057 哈尔滨三联药业股份有限公司 关于控股子公司变更法定代表人并完成工商变更登记的公告 法定代表人：张道旭 备查资料 1、黑龙江哈三联生物技术创新中心有限公司营业执照。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2023 年 8 月 17 日 变更后： 法定代表人：李宏伟 除法定代表人变更外，黑龙江哈三联生物技术创新中心有限公司《营业执照》 的其他登记事项均保持不变。 ...

证券代码：002900 证券简称：哈三联 公告编号：2023-033 哈尔滨三联药业股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者网上集体接待日活 动暨业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前 ...

（问题征集专题页面二维码） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路演 APP， 参与本次互动交流。活动时间为 2023 年 5 月 15 日（周一）14:00-16:30。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 12 日（周五）12:00 前访问 https://ir.p5w.ne ...

Financial Performance - The company's revenue for Q1 2023 was CNY 342,147,502.19, representing a 33.29% increase compared to CNY 256,694,410.27 in the same period last year[5] - Net profit attributable to shareholders reached CNY 39,163,800.70, a significant increase of 3,445.73% from a loss of CNY 1,170,560.94 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 20,511,251.64, up 422.73% from CNY 3,923,905.57 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.13, compared to a loss of CNY 0.02 per share in the same quarter last year, reflecting a 750.00% increase[5] - Total operating revenue for Q1 2023 reached CNY 342,147,502.19, a 33.33% increase from CNY 256,694,410.27 in Q1 2022[21] - Net profit for Q1 2023 was CNY 38,293,510.10, compared to a net loss of CNY 1,819,460.26 in the same period last year[22] - Operating profit for Q1 2023 was CNY 43,300,037.81, a significant recovery from a loss of CNY 2,724,332.84 in Q1 2022[22] Cash Flow - The net cash flow from operating activities was CNY 26,205,083.12, a turnaround from a negative CNY 7,765,583.82, marking a 437.45% improvement[5] - Cash flow from operating activities was CNY 312,367,935.53, compared to CNY 254,545,834.16 in Q1 2022, indicating improved cash generation[24] - Total cash inflow from operating activities reached ¥336,143,482.69, up from ¥260,304,215.74 in the same period last year, indicating a growth of approximately 29.1%[25] - Cash outflow from operating activities was ¥309,938,399.57, compared to ¥268,069,799.56 in Q1 2022, reflecting an increase of about 15.7%[25] - The net cash flow from investing activities was -¥43,328,299.74, a decline from a positive cash flow of ¥447,183,988.76 in Q1 2022[25] - The net cash flow from financing activities was ¥46,866,238.08, an increase from ¥26,603,539.27 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,386,123,646.22, a 3.34% increase from CNY 3,276,788,333.47 at the end of the previous year[5] - Total liabilities increased to CNY 1,295,843,183.87 from CNY 1,224,801,381.22 year-over-year[19] - The company's equity attributable to shareholders was CNY 2,079,834,612.44, up 1.92% from CNY 2,040,670,811.74 at the end of the last year[5] - Long-term investments increased to CNY 655,019,843.89, up from CNY 646,866,264.65, indicating a stable investment strategy[19] Research and Development - The company increased its investment in research and development, with development expenditures rising by 50.43% to CNY 15,898,085.31 from CNY 10,568,155.52[9] - Research and development expenses increased to CNY 20,228,682.35, up from CNY 15,964,277.61 in the previous year, reflecting a focus on innovation[21] Other Income and Expenses - The company reported a significant increase in other income, which reached CNY 11,375,287.99, a 730.23% rise from CNY 1,370,131.73 in the previous year[11] - The fair value change income was CNY 7,145,181.77, a 175.90% increase compared to a loss of CNY 9,413,631.01 in the same period last year[11] - The company paid ¥32,750,632.17 in various taxes, which is a 33.78% increase compared to the same period last year, attributed to higher revenue[12] Shareholder Information - The top shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 123,705,000 shares, indicating strong insider ownership[14]

Financial Performance - The company's operating revenue for 2022 was ¥1,028,413,617.71, an increase of 8.73% compared to ¥945,799,422.97 in 2021 [20]. - The net profit attributable to shareholders for 2022 was ¥30,210,042.44, a decrease of 91.39% from ¥350,951,064.21 in 2021 [20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,860,891.68, a significant increase of 107.31% compared to -¥148,479,133.39 in 2021 [20]. - The net cash flow from operating activities reached ¥144,641,853.00, a remarkable increase of 1,254.01% from -¥12,533,851.80 in 2021 [20]. - The total assets at the end of 2022 were ¥3,276,788,333.47, reflecting a growth of 6.89% from ¥3,065,517,046.80 at the end of 2021 [20]. - The net assets attributable to shareholders decreased by 2.89% to ¥2,040,670,811.74 at the end of 2022 from ¥2,101,449,040.99 at the end of 2021 [20]. - The basic earnings per share for 2022 was ¥0.10, down 91.15% from ¥1.13 in 2021 [20]. - The weighted average return on equity for 2022 was 1.46%, a decrease of 16.65% from 18.11% in 2021 [20]. - The company reported a total of ¥19,349,150.76 in non-recurring gains for 2022, compared to ¥499,430,197.60 in 2021 [25]. - The company reported a cash dividend of 1.00 yuan per 10 shares, amounting to a total cash dividend of 31,656,005 yuan, which represents 100% of the total profit distribution [150]. Risk Management - The company faces various risks including industry policy risks, drug research and development risks, and fluctuations in raw material prices [4]. - The company has a comprehensive risk management strategy to address potential investment risks and ensure shareholder value [4]. Business Operations - The company has not reported any changes in its main business since its listing, indicating stability in operations [19]. - The company has maintained its full ownership of several subsidiaries, indicating a strong control over its business operations [14]. - The company has a dedicated investor relations team to facilitate communication with shareholders and stakeholders [17]. - The company has established a competitive salary policy that includes fixed and performance-based components to incentivize employee performance [146]. Product Development - The company has a total of 153 drug varieties and 254 production licenses, with 149 varieties included in the national medical insurance directory and 48 in the national essential drug list [30]. - The company has obtained drug registration certificates for six products during the reporting period, including Edaravone Injection and Olanzapine Oral Disintegrating Tablets, enhancing its product portfolio [33]. - The company has launched three oral health products in the health sector, focusing on cardiovascular health, beauty, and sleep improvement, utilizing beneficial ingredients like GABA and DHA [36]. - The company is focusing on the development of new health products, which are expected to drive revenue growth in the coming years [66]. - The company is enhancing its injection product quality through consistency evaluations for products like 克林霉素磷酸酯注射液 and 甲硝唑氯化钠注射液, which will strengthen its competitive position [64]. Market Trends - The pharmaceutical industry in China is expected to continue growing due to increasing healthcare demands driven by an aging population and improved living standards [28]. - The Chinese pharmaceutical industry is undergoing a transformation driven by the "14th Five-Year Plan," emphasizing innovation and quality compliance as key themes for high-quality development [29]. - The ongoing national drug procurement reform has expanded to include biological products and traditional Chinese medicine, which will accelerate the elimination of weaker pharmaceutical companies [29]. - The pharmaceutical industry is expected to see intensified competition focused on cost control and quality improvement in the future [29]. Corporate Governance - The company emphasizes the importance of accurate financial reporting and has confirmed the integrity of its annual report by its board of directors [4]. - The company maintains a complete and independent business system, ensuring no asset or financial encroachment by controlling shareholders [118]. - The company has established independent financial departments and accounting systems, ensuring no interference from controlling shareholders in financial decisions [119]. - The company has a clear governance structure with defined roles and responsibilities across its departments [119]. Environmental Responsibility - The company has implemented measures to ensure compliance with environmental protection laws and standards, including the discharge of pollutants [162]. - The company invested over 1 million yuan in environmental protection since its establishment, with more than 500,000 yuan spent in 2022 on pollution detection and waste disposal [176]. - The company has established a waste storage facility for hazardous waste, complying with national standards, and has a contract for safe disposal with a local environmental company [168]. Employee Engagement - A total of 677,000 restricted shares were granted to 175 core talents as part of the equity incentive program, enhancing employee engagement [47]. - The company has a structured training program aimed at enhancing employee skills and management capabilities, with a focus on continuous development [147]. - The total number of employees at the end of the reporting period was 1,721, with 1,293 in the parent company and 428 in major subsidiaries [144]. Future Outlook - The company plans to enhance cost control and resource allocation to ensure the achievement of annual operational targets [105]. - The management has indicated a positive outlook for future growth, with expectations of increased revenue and market share in the coming years [125]. - The company is exploring potential acquisitions to further strengthen its product portfolio and market presence [131].

索 引 号 bm56000001/2017-00005754 分 类 预先披露;预先披露 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书 （申报稿 2017年4月17日报送） 根据《证券法》第二十一条和《首次公开发行股票并上市管理办法》第五十八条、《首次公开发行股票并在创业 板上市管理办法》第四十条的规定，申请文件受理后、发行审核委员会审核前，发行人应当将招股说明书（申报稿） 在中国证监会网站预先披露。 发布机构 证监会 发文日期 【打印】 【关闭窗口】 名 称 哈尔滨三联药业股份有限公司首次公开发行股票并上市招股说明书（申报稿 2017年4月17日 报送） 文 号 主 题 词 ...

证券代码：002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------| | | | | | | □ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □路演活动 | | | 类别 | 现场参观 | | | | | 其他（深交所、黑龙江证监局、黑龙江省金融局联合举办 | | | | "东北资本市场服务周——走进哈三联"活动） | | | 1 、通过江海证券报名的 | 10 余名投资者； | | 参与单位名称及 | 2 、全景网记者 3 | 人； | | 人员姓名 | 3 、深交所投资者教育中心 | 2 人。 | | 时间 | 2020 年 11 月 10 | 日 9:30-12:00 | | 地点 | | 哈尔滨市利民开发区北京路哈尔滨三联药业股份有限公司 | ...

编号：2022-001 证券代码：002900 证券简称：哈三联 哈尔滨三联药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------| | | | | | | □特定对象调研 □分析师会议 | | | | □媒体采访 | 业绩说明会 | | 投资者关系活 动类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | | | 参与单位名称 及人员姓名 | 参与"黑龙江辖区上市公司 说明会"的全体投资者 | 2022 年投资者网上集体接待日暨业绩 | | 时间 | 2022 年 5 月 12 日 | 14:30-16:30 | | 地点 | （ | 全景网"投资者关系互动平台" https ...

Financial Performance - The company's revenue for Q3 2022 was ¥257,147,319.28, representing a year-on-year increase of 9.97%[5] - Net profit attributable to shareholders was ¥831,010.25, a significant increase of 101.79% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses reached ¥4,068,960.30, up 136.23% year-on-year[5] - Total operating revenue for the third quarter of 2022 was CNY 761,888,173.20, an increase of 7.63% compared to CNY 707,663,354.04 in the same period last year[20] - Net profit for the third quarter was CNY 18,611,875.84, a significant decrease of 96.55% from CNY 539,038,150.98 in the previous year[20][21] - Earnings per share (EPS) decreased to CNY 0.07 from CNY 1.74 in the same quarter last year[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,247,038,628.19, reflecting a 5.92% increase from the end of the previous year[5] - The company's total liabilities increased to CNY 1,211,085,312.39, up from CNY 949,044,449.40 year-on-year[20] - Non-current liabilities rose to CNY 622,377,625.41, compared to CNY 412,429,977.04 in the previous year, indicating a 50.83% increase[20] - The total equity attributable to shareholders decreased to CNY 2,023,655,122.29 from CNY 2,101,449,040.99, a decline of 3.71%[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥59,461,141.12, a substantial increase of 468.89%[5] - Cash received from operating activities increased by 55.32% to ¥29,866,601.79, driven by higher revenue and government subsidies[14] - Cash inflow from operating activities was CNY 857,149,727.90, compared to CNY 814,839,472.33 in the previous year, reflecting a slight increase[22] - The net cash flow from operating activities was CNY 59,461,141.12, a significant improvement compared to a net outflow of CNY 16,119,145.36 in the same period last year[23] - The company's cash flow from operating activities showed a positive trend, indicating improved operational efficiency[23] Investment and Financing Activities - The company reported a significant drop in investment income, which fell to CNY 36,189,694.15 from CNY 588,101,455.17 year-on-year[20] - Cash received from investment income decreased by 40.04% to ¥6,844,946.50, attributed to a decline in investment returns from financial products[14] - The company has increased its long-term borrowings by 102.35% to ¥414,497,705.99, indicating a strategy to enhance liquidity[10] - The company received CNY 431,000,000.00 in borrowings during the quarter, an increase from CNY 411,600,000.00 in the same period last year[23] - The total cash inflow from financing activities was CNY 478,290,777.34, compared to CNY 413,065,600.00 in the previous year[23] Government Subsidies and Other Income - The company received government subsidies amounting to ¥8,289,802.28 during the reporting period, which is a key contributor to the increase in other income[7] - Tax refunds received decreased by 53.00% to ¥11,380,692.29 compared to ¥24,215,995.98 in the same period last year, primarily due to a reduction in VAT refunds[14] Shareholder Information - The number of common shareholders at the end of the reporting period was 37,849, with the largest shareholder holding 39.07% of the shares[15] Research and Development - Research and development expenses were CNY 63,504,251.30, down from CNY 70,698,558.74, indicating a reduction of 10.3%[20]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥504.74 million, representing a 6.52% increase compared to ¥473.83 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company was approximately ¥20.51 million, a significant decrease of 96.50% from ¥586.29 million in the previous year[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥8.30 million, an increase of 127.41% compared to a loss of ¥30.29 million in the same period last year[20]. - The net cash flow from operating activities was approximately ¥30.56 million, a substantial increase of 261.31% from a negative cash flow of ¥18.95 million in the previous year[20]. - The total assets at the end of the reporting period were approximately ¥3.17 billion, reflecting a 3.52% increase from ¥3.07 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company decreased by 3.74% to approximately ¥2.02 billion from ¥2.10 billion at the end of the previous year[20]. - The basic earnings per share were ¥0.07, down 96.30% from ¥1.89 in the same period last year[20]. - The diluted earnings per share were also ¥0.07, reflecting the same percentage decrease of 96.30% compared to the previous year[20]. - The weighted average return on net assets was 0.97%, a decrease of 27.37% from 28.34% in the previous year[20]. Revenue and Growth - The company reported a total non-operating income of CNY 12,202,138.53, primarily driven by government subsidies and fair value changes from trading financial assets[24]. - The company received government subsidies amounting to CNY 4,588,872.21 during the reporting period, which were recognized as income[24]. - The fair value changes from trading financial assets, particularly from investments in Hong Kong stocks, contributed CNY 9,571,985.02 to the income[24]. - The pharmaceutical sector accounted for 98.04% of total revenue, with a year-on-year growth of 9.64%[44]. - The solid preparation segment saw a revenue increase of 38.39%, primarily due to higher sales of Mianserin tablets[46]. - The company experienced a 190.01% increase in revenue from import and export trade, contributing significantly to overall growth[44]. Research and Development - The R&D team consists of 285 personnel, accounting for approximately 16.24% of the total workforce, focusing on innovative drug development and consistency evaluation projects[37]. - The company has developed a rich product line covering multiple therapeutic areas, including neurological, cardiovascular, and oncology diseases, enhancing its competitive advantage in brand and quality[35]. - The company is committed to enhancing its research and development capabilities to innovate and improve its product offerings[174]. Market Strategy and Expansion - The company plans to expand its market presence by entering three new provinces by the end of 2022[97]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[97]. - A new marketing strategy focusing on digital channels is set to be implemented, aiming for a 20% increase in online sales[97]. - The company is focusing on reducing operational costs by 10% through various efficiency measures and process optimizations[100]. Environmental and Compliance - The company has established facilities for hazardous waste storage and signed a contract for the disposal of hazardous waste with Heilongjiang Jingshenghua Environmental Technology Co., Ltd.[92]. - The company’s wastewater treatment facilities ensure that pharmaceutical wastewater is treated to meet standards before being discharged to the local sewage treatment plant[92]. - The company has implemented measures to reduce carbon emissions, although specific details were not provided[93]. - There were no administrative penalties received due to environmental issues during the reporting period[93]. - The company has developed an emergency response plan for environmental incidents, which has been filed with the local environmental protection bureau[93]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of its stock listing[96]. - Major shareholders are restricted from reducing their holdings within 12 months of the stock listing, with a price reduction not below the issuance price[96]. - The company ensures that any share transfers comply with the Shenzhen Stock Exchange rules and relevant regulations[96]. - The company has established a clear framework for shareholding commitments to maintain market stability[96]. Future Outlook - Future guidance estimates a revenue growth of 10-15% for the next fiscal year[97]. - The company plans to continue expanding its market presence and investing in new product development to drive future revenue growth[174]. - The company is committed to ongoing research and development efforts to innovate and introduce new technologies in its product offerings[126].